| scholarly article | Q13442814 |
| P50 | author | James Douketis | Q100404477 |
| P2093 | author name string | Jeffrey S Ginsberg | |
| Alexander G Turpie | |||
| Jim A Julian | |||
| Michael Gent | |||
| Sharon Jackson | |||
| Paul Ockelford | |||
| Susan Solymoss | |||
| Clive Kearon | |||
| Jack Hirsh | |||
| Betsy MacKinnon | |||
| Fixed-Dose Heparin (FIDO) Investigators | |||
| P433 | issue | 8 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | heparin | Q190016 |
| venous thromboembolism | Q9397786 | ||
| P304 | page(s) | 935-942 | |
| P577 | publication date | 2006-08-01 | |
| P1433 | published in | The Journal of the American Medical Association | Q1470970 |
| P1476 | title | Comparison of fixed-dose weight-adjusted unfractionated heparin and low-molecular-weight heparin for acute treatment of venous thromboembolism | |
| P478 | volume | 296 |
| Q36522975 | A Prospective Study of Adequacy of Anticoagulation with Fixed Dose Weight Adjusted Unfractionated Heparin in Patients with Deep Vein Thrombosis |
| Q37104719 | A descriptive evaluation of unfractionated heparin use during pregnancy |
| Q37788951 | Acute pulmonary embolism. Part 2: treatment |
| Q33435357 | Anticoagulation Therapy in Patients with Chronic Kidney Disease |
| Q24633053 | Antithrombotic therapy for VTE disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines |
| Q91788872 | Asymptomatic "breakthrough" thrombosis and anticoagulant "failure": Keep calm and carry on |
| Q34437785 | Benchmark for time in therapeutic range in venous thromboembolism: a systematic review and meta-analysis |
| Q37454454 | Clinical pearls in thrombosis and anticoagulation |
| Q39788611 | Community-based treatment of venous thromboembolism with a low-molecular-weight heparin and warfarin |
| Q39874027 | Comparison of pain and ecchymosis with low-molecular-weight heparin vs. unfractionated heparin in patients requiring bridging anticoagulation after warfarin interruption: a randomized trial |
| Q37165370 | Current strategies in prophylaxis and treatment of venous thromboembolism. |
| Q26827598 | Deep Venous Thrombosis: An Interventionalist's Approach |
| Q38851927 | Drug Treatment of Venous Thromboembolism in the Elderly. |
| Q43088071 | Enhanced antithrombotic effects of unfractionated heparin in rats after repeated oral doses and its relationship to endothelial heparin concentration |
| Q52352122 | Enoxaparin pretreatment effect on local and systemic inflammation biomarkers in the animal burn model. |
| Q33392669 | Established Venous Thromboembolism Therapies: Heparin, Low Molecular Weight Heparins, and Vitamin K Antagonists, with a Discussion of Heparin-Induced Thrombocytopenia |
| Q37313581 | Evaluation of the Management of Acute Venous Thromboembolism and Its Outcomes: One Institution's Experience. |
| Q24632951 | Evidence-based management of anticoagulant therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines |
| Q35642521 | Factors associated with adverse outcomes in outpatients presenting with pulmonary embolism: the Worcester Venous Thromboembolism Study |
| Q34550908 | Fixed dose subcutaneous low molecular weight heparins versus adjusted dose unfractionated heparin for the initial treatment of venous thromboembolism |
| Q24235236 | Fixed dose subcutaneous low molecular weight heparins versus adjusted dose unfractionated heparin for venous thromboembolism |
| Q28079081 | Guidance for the practical management of the heparin anticoagulants in the treatment of venous thromboembolism |
| Q35525678 | Heparin and warfarin anticoagulation intensity as predictors of recurrence after deep vein thrombosis or pulmonary embolism: a population-based cohort study |
| Q37903951 | How to prevent, treat, and overcome current clinical challenges of VTE. |
| Q46626799 | Initial management of deep venous thrombosis in the outpatient setting |
| Q33375535 | Latest medical treatment strategies for venous thromboembolism |
| Q42907039 | Management of Pulmonary Embolism: 2010 State-of-the-Art Update |
| Q36812767 | Management of venous thromboembolism in patients with cancer: role of dalteparin |
| Q35154142 | Measurement of non-VKA oral anticoagulants versus classic ones: the appropriate use of hemostasis assays. |
| Q45865979 | Measurement of non-coumarin anticoagulants and their effects on tests of Haemostasis: Guidance from the British Committee for Standards in Haematology |
| Q33795571 | Measures of vitamin K antagonist control reported in atrial fibrillation and venous thromboembolism studies: a systematic review |
| Q37806825 | New Synthetic Antithrombotic Agents for Venous Thromboembolism: Pentasaccharides, Direct Thrombin Inhibitors, Direct Xa Inhibitors |
| Q42907043 | New and Emerging Anticoagulant Therapies for Venous Thromboembolism |
| Q38071934 | New oral therapies for the prevention and treatment of venous thromboembolism |
| Q38166368 | New prospective for the management of low-risk pulmonary embolism: prognostic assessment, early discharge, and single-drug therapy with new oral anticoagulants |
| Q33399576 | Parenteral anticoagulants: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines |
| Q35752584 | Perioperative management of antithrombotic therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines |
| Q39029202 | Pharmacological management of pulmonary embolism |
| Q37740303 | Potential of new anticoagulants in patients with cancer |
| Q91742238 | Preventive application of low molecular weight heparin ameliorates peripherally inserted central catheter-related venous thrombosis |
| Q35011270 | Pulmonary embolism in pregnancy. |
| Q37099148 | Recent advances in cardiorespiratory medicine: management of pulmonary embolism and prevention of venous thromboembolism, recent treatment strategies in childhood asthma, and dermatological adverse reactions to cardiovascular drugs |
| Q37953154 | Review for hospitalists: acute pulmonary embolism |
| Q85883528 | Simplifying and interpreting the FACTS of noninferiority trials: A stepwise approach |
| Q24240038 | Subcutaneous unfractionated heparin for the initial treatment of venous thromboembolism |
| Q38962411 | Subcutaneous unfractionated heparin for the initial treatment of venous thromboembolism. |
| Q42794591 | Subcutaneous unfractionated heparin for treatment of venous thromboembolism in end-stage renal disease |
| Q39266324 | The danger of relying on the APTT and PT in patients on DOAC therapy, a potential patient safety issue |
| Q47644500 | The diagnosis and treatment of venous thromboembolism in asian patients. |
| Q38669011 | Therapeutic monitoring of unfractionated heparin - trials and tribulations |
| Q93501215 | Thromboembolism |
| Q33840400 | Thromboembolism. |
| Q33401715 | Treatment of established thrombotic events in patients with cancer |
| Q33387992 | Treatment of venous thromboembolism |
| Q36561057 | Treatment of venous thromboembolism - effects of different therapeutic strategies on bleeding and recurrence rates and considerations for future anticoagulant management |
| Q37541850 | Treatment of venous thromboembolism: guidelines translated for the clinician |
| Q33386920 | Update on heparin: what do we need to know? |
| Q38157555 | Update on pharmacologic therapy for pulmonary embolism |
| Q37199934 | Use of anticoagulants in elderly patients: practical recommendations |
| Q24631121 | Venous thromboembolic disease |
| Q38189131 | What are the pharmacotherapy options for treating venous thromboembolism in cancer patients? |
| Q93505940 | What's new in the other general journals |
| Q84007375 | [New anticoagulant drugs for atrial fibrillation. Feasibility and necessity of monitoring] |
Search more.